ZIOPHARM Oncology to Participate at Upcoming CAR-TCR Summit
September 01 2017 - 7:05AM
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical
company focused on new immunotherapies, today announced that the
Company will participate at the upcoming CAR-TCR Summit 2017. The
summit is being held September 5-8, 2017 at the Seaport Hotel &
World Trade Center in Boston.
Laurence Cooper, M.D., Ph.D., Chief Executive
Officer of ZIOPHARM, will participate in the Industry Leaders'
Fireside Chat on Wednesday, September 6, 2017 beginning at 8:45
a.m. ET. In addition, research highlighting the Sleeping
Beauty non-viral gene transfer system will be presented during
an oral presentation session.
"Sleeping Beauty is one of the most
clinically-advanced non-viral cell engineering platforms in
development and holds the potential to enable personalized
solutions and opens the door to point-of-care manufacturing
approaches to rapidly generate T cells, help lower cost, and expand
access to innovative therapies,” said Dr. Cooper. “Our human data
reveal the therapeutic potential of these genetically modified T
cells and the shortened production circumvents the complexities and
high cost typically associated with viral-based
approaches. Sleeping Beauty offers a scalable solution to
redirecting T-cell specificity to both blood cancers and solid
tumors using CARs and TCRs."
Details for the oral presentation are as
follow:
Title: Sleeping Beauty: An
Update on the Non-Viral Transduction Platform for CAR
TherapiesPresenter: Partow Kebriaei,
Professor, Department of Stem Cell Transplantation & Cellular
Therapy, The University of Texas MD Anderson Cancer
CenterTrack: CAR-TCR Discovery
StreamDate and Time: Thursday, September 7,
2017, 3:20 p.m. – 3:50 p.m. ET
About ZIOPHARM Oncology,
Inc.
ZIOPHARM Oncology is a Boston,
Massachusetts-based biotechnology company employing innovative gene
expression, control and cell technologies to deliver safe,
effective and scalable cell- and viral-based therapies for the
treatment of cancer and graft-versus-host-disease. The Company's
immuno-oncology programs, in collaboration with Intrexon
Corporation (NYSE:XON) and the MD Anderson Cancer Center, include
chimeric antigen receptor T cell (CAR-T) and other adoptive
cell-based approaches that use non-viral gene transfer methods for
broad scalability. The Company is advancing programs in multiple
stages of development together with Intrexon Corporation's
RheoSwitch Therapeutic System® (RTS®) technology, a switch to
turn on and off, and precisely modulate, gene expression in order
to improve therapeutic index. The Company's pipeline includes a
number of cell-based therapeutics in both clinical and preclinical
testing which are focused on hematologic and solid tumor
malignancies.
Forward-Looking Safe-Harbor
Statement
This press release contains certain
forward-looking information about ZIOPHARM Oncology, Inc. that is
intended to be covered by the safe harbor for "forward-looking
statements" provided by the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts, and in some cases can be identified
by terms such as "may," "will," "could," "expects," "plans,"
"anticipates," and "believes." These statements include, but are
not limited to, statements regarding the Company's plans and
expectations regarding its securities offerings, fundraising
activities and financial strategy, the progress, timing and results
of preclinical and clinical trials involving the Company's drug
candidates, and the progress of the Company's research and
development programs. All of such statements are subject to certain
risks and uncertainties, many of which are difficult to predict and
generally beyond the control of the Company, that could cause
actual results to differ materially from those expressed in, or
implied by, the forward-looking statements. These risks and
uncertainties include, but are not limited to: our ability to
finance our operations and business initiatives and obtain funding
for such activities, whether chimeric antigen receptor T cell
(CAR-T) approaches, Ad-RTS-hIL-12, TCR and NK cell-based therapies,
or any of our other therapeutic candidates will advance further in
the preclinical or clinical trials process and whether and when, if
at all, they will receive final approval from the U.S. Food and
Drug Administration or equivalent foreign regulatory agencies and
for which indications; whether chimeric antigen receptor T cell
(CAR-T) approaches, Ad-RTS-hIL-12, TCR and NK cell-based therapies,
and our other therapeutic products will be successfully marketed if
approved; the strength and enforceability of our intellectual
property rights; competition from other pharmaceutical and
biotechnology companies; and the other risk factors contained in
our periodic and interim reports filed from time to time with the
Securities and Exchange Commission, including but not limited to,
our Annual Report on Form 10-K for the fiscal year ended December
31, 2016 and our Quarterly Report on Form 10-Q for the quarter
ended June 30, 2017. Readers are cautioned not to place undue
reliance on these forward-looking statements that speak only as of
the date hereof, and we do not undertake any obligation to revise
and disseminate forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence
of or non-occurrence of any events.
TrademarksRheoSwitch
Therapeutic System® and RTS® are registered trademarks of
Intrexon Corporation.
Contact:
David Pitts
Argot Partners
212-600-1902
david@argotpartners.com
ZIOPHARM Oncology (NASDAQ:ZIOP)
Historical Stock Chart
From Mar 2024 to Apr 2024
ZIOPHARM Oncology (NASDAQ:ZIOP)
Historical Stock Chart
From Apr 2023 to Apr 2024